Dimethylphenylpiperazinium Iodide

Subscribe to Selected New Research on Dimethylphenylpiperazinium Iodide

61 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Description: A selective nicotinic cholinergic agonist used as a research tool. DMPP activates nicotinic receptors in autonomic ganglia but has little effect at the neuromuscular junction.

Also Known As:

1,1-Dimethyl-4-phenylpiperazine Iodide; Dimethylphenylpiperazinium; 1,1 Dimethyl 4 phenylpiperazine Iodide; Iodide, 1,1-Dimethyl-4-phenylpiperazine; Iodide, Dimethylphenylpiperazinium; DMPP; Piperazinium, 1,1-dimethyl-4-phenyl-, iodide

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Piperazines: 17

Dimethylphenylpiperazinium Iodide: 61

Experts

1.	Prado, Wiliam A: 1 article (08/2004)
2.	Segalla, Daniel K: 1 article (08/2004)

Related Diseases

1.	Ganglion Cysts (Ganglion) 11/23/1979 - "Although the potency varied considerably all of the compounds tested lowered the blood pressure, which appeared to be the result of ganglion blocking properties as determined by their reduction of the pressor response to dimethylphenylpiperazinium and the blockage of the contraction of the preganglionically stimulated cat nictitating membrane" 11/01/1953 - "Cardiovascular action of 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP); a ganglion stimulating agent useful in the diagnosis of pheochromocytoma." 12/01/2000 - "After pretreatment with atropine (0.2 mg/kg), an intravenous bolus (4 microg/kg) of a nicotinic ganglion stimulant [1,1-dimethyl-4-phenylpiperazinium iodide (DMPP)] was given at rest and during treadmill exercise at graded intensities" 01/01/1997 - "The ganglionic stimulant dimethylphenyl-piperazinium-iodide (DMPP) exerted dual actions on blood pressure: a rapid and short-term pressor reaction (phase I) resulting from catecholamine release elicited by ganglion stimulation, followed by a more sustained blood pressure elevation (phase II) resulting from the circulating catecholamines released from the adrenal medulla" 01/01/1996 - "RESULTS: In atropine-treated animals, electrical vagal stimulation or arterial bolus injection of the ganglion stimulant dimethyl phenylpiperazinium iodide (DMPP) evoked inhibitory responses that varied from a brisk relaxation, interrupted by a poststimulus excitatory motility (biphasic response), to a long-lasting relaxation (monophasic response)" Get all the results and reference details, order at left...
2.	Hemorrhagic Shock 04/01/1996 - "The reversal of experimental hemorrhagic shock induced by nicotine and dimethylphenylpiperazinium is adrenal-dependent." 07/15/1992 - "Reversal of experimental hemorrhagic shock by dimethylphenylpiperazinium (DMPP)." 07/15/1992 - "In a rat model of hemorrhagic shock which caused the death of all control rats within 30 min, i.v. injection of the ganglion-stimulating drug dimethylphenylpiperazinium (DMPP) caused a dose-dependent reversal of the shock condition--without the need for reinfusion of the shed blood--starting from the dose of 4 ng/kg i.v. Shock reversal was associated with the mobilization of residual blood and improvement in blood flow, particularly at the carotid level" 04/01/1996 - "In a rat model of volume-controlled hemorrhagic shock causing the death of all control animals within 30 min, the intravenous injection of either nicotine (50 micrograms/kg) or dimethylphenylpiperazinium (DMPP) (0.5 micrograms/kg) produced a rapid and sustained reversal of the shock condition, with 100% survival 2 h after treatment" Get all the results and reference details, order at left...
3.	Shock 04/01/1996 - "Bilateral adrenalectomy completely prevented the anti-shock effect of the two drugs, even though administered at higher doses (150 micrograms/kg in the case of nicotine; 10 micrograms/kg in the case of DMPP)" 04/01/1996 - "It is concluded that stimulation of adrenaline release plays a fundamental role in the mechanism of action of nicotine- and DMPP-induced shock reversal." 07/15/1992 - "In a rat model of hemorrhagic shock which caused the death of all control rats within 30 min, i.v. injection of the ganglion-stimulating drug dimethylphenylpiperazinium (DMPP) caused a dose-dependent reversal of the shock condition--without the need for reinfusion of the shed blood--starting from the dose of 4 ng/kg i.v. Shock reversal was associated with the mobilization of residual blood and improvement in blood flow, particularly at the carotid level" 04/01/1996 - "In a rat model of volume-controlled hemorrhagic shock causing the death of all control animals within 30 min, the intravenous injection of either nicotine (50 micrograms/kg) or dimethylphenylpiperazinium (DMPP) (0.5 micrograms/kg) produced a rapid and sustained reversal of the shock condition, with 100% survival 2 h after treatment" Get all the results and reference details, order at left...
4.	Vomiting 01/01/1986 - "DMPP injected in 0.2-2.0 mg doses into the cerebral ventricle produced dose-dependent vomiting, which was abolished after ablation of area postrema" 01/01/1986 - "Dimethylphenylpiperazinium-induced vomiting: nicotinic mediation in area postrema." 09/01/1983 - "In cats with ablations of the area postrema, nicotine and DMPP injected ICV did not produce the vomiting response, but ear twitching and panting still occurred" 09/01/1983 - "On a molar basis, nicotine evoked stronger effects overall in terms of the three responses studied, but the DMPP-induced vomiting and ear twitching responses, while weaker, were of longer duration" 01/01/1986 - "It is postulated that DMPP evokes vomiting by its action on nicotinic receptors of nerve cells within the area postrema but not on catecholaminergic, serotonergic, or cholinergic receptors" Get all the results and reference details, order at left...
5.	Cough 04/01/1978 - "These results indicate that the mechanism of CLR with DMPP is different from that of peripherally-induced cough and the carotid body chemoreceptor plays an important role in CLR with DMPP" 04/01/1978 - "To investigate the mechanism of the cough-like reflex (CLR), we employed 1.1-dimethyl-4-phenylpiperazinium iodide (DMPP)" 03/01/1975 - "Thus, it appears that the mechanism of CLR with DMPP is different from that in the cough reflex" 03/01/1975 - "Compared with the curve of a cough-like reflex (CLR) induced by DMPP, the curve of a cough induced by electrical stimulation of the tracheal mucosa was similar to that of a cough in humans" 06/01/1982 - "Such as increase in the power of the 2 approximately 100 Hz band components toward the other frequency band components during the cough reflex was not observed after an i.v. administration of DMPP and lobeline, but the power increased extended over every frequency band" Get all the results and reference details, order at left...
26 Diseases and 61 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Dimethylphenylpiperazinium Iodide
2.	Nicotine
3.	Mecamylamine
4.	Pancuronium (Pavulon)
5.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
6.	Atropine (Hyoscyamine)
7.	Nicotinic Agonists
8.	Epinephrine (Adrenaline)
9.	Acetylcholine (Acetylcholine Chloride)
10.	Hexamethonium (Hexamethonium Bromide)
85 Drugs and Important Bio-Agents and 57 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Adrenalectomy
2 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>